Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

NCT00049127 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00049127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00049127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2003
Completion date
September 1, 2019
Enrollment
64 (actual)
Sites
229

Conditions

As the registry lists them; a condition with its own page is linked.

adult anaplastic oligodendroglioma, adult mixed glioma, adult oligodendroglioma, recurrent adult brain neoplasm